Karol Sikora looks at monoclonal antibodies, the rising stars of the biotechnology era.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sikora, K. Who needs monoclonals?. Nature 304, 97–100 (1983). https://doi.org/10.1038/304097a0
Published:
Issue Date:
DOI: https://doi.org/10.1038/304097a0